About The Study: This study compared the proportions of racial and ethnic groups in 221 phase 1 clinical trials of drugs for metastatic cancer from 2000 to 2018 with population-based cancer registry data and found worsening disparities over time in the accrual of patients from racial and ethnic minority groups. These findings may represent widening inequalities in access to trial sites and worsening systemic biases. More efforts are needed to diversify phase 1 cancer drug trials to improve equity in access to new treatments and to ensure that safety and efficacy findings from early drug trials are generalizable across populations.
Authors: C. Jillian Tsai, M.D., Ph.D., of the Princess Margaret Cancer Centre in Toronto, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.30884)